Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Colorectal cancer was found to be the most common malignancy and cause of death among patients with classic familial adenomatous polyposis.

Dr. William Sellers is a leading cancer researcher who currently serves as a Core Institute member and Director of the cancer ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

With celebrities singing the praises of full-body MRI scans, a growing number of people are coughing up the cash for ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

The internationally renowned Dana-Farber Cancer Institute will operate the cancer clinic now under construction on the Sturdy ...

Dana-Farber Cancer Institute and Boston Children’s Cancer and Blood Disorders Center have received a 4-year, $5 million ...

Study Health announced it will be partnering with Dana-Farber Cancer Institute to provide cancer service at its hospital in ...

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...